Full Press Release Details
CervoMed Announces Publication in Neurology Results Showing a Blood Test at Study Entry Identified Patients Who Demonstrated Substantial Response to Neflamapimod in Dementia with Lewy Bodies.
CRVO
CervoMed Announces Publication in Neurology Results Showing a Blood Test at Study Entry Identified Patients Who Demonstrated Substantial Response to Neflamapimod in Dementia with Lewy Bodies
Key Takeaway: CervoMed Announces Publication in Neurology Results Showing a Blood Test at Study Entry Identified Patients Who Demonstrated Substantial Response to Neflamapimod in Dementia with Lewy Bodies
Price reaction · baseline $4.98 (2023-09-05 close) · hit after-hours · clean, no other CRVO news in the window
day 0 close · peak
-9.2%
day 1
+5.5%
day 3
+6.4%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
6.8%
average across 6 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
Neflamapimod
Phase 2 · Moderate to Severe Acute Ischaemic Stroke